11:50 AM ET
Earnings Call
▶ Call
uniQure Earnings Call: Key Takeaways
uniQure is transitioning to a commercial-stage entity with FDA priority review for AMT-130, backed by a strong $768.4 million cash position and significant slowing of Huntington's disease progression.
- Call
- Nov 4, 2026, 8:30 AM ET